Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators
Rebecca B. Price, Nicholas Kissel, Andrew Baumeister, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 12, pp. 5096-5112
Open Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape
Manish K. Jha, Sanjay J. Mathew
American Journal of Psychiatry (2023) Vol. 180, Iss. 3, pp. 190-199
Closed Access | Times Cited: 58
History repeating: guidelines to address common problems in psychedelic science
Michiel van Elk, Eiko I. Fried
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 51
Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics?
Kenji Hashimoto
European Archives of Psychiatry and Clinical Neuroscience (2024)
Open Access | Times Cited: 28
Antidepressant mechanisms of ketamine: a review of actions with relevance to treatment-resistance and neuroprogression
August P. M. Lullau, E. Haga, Eivind Haga Ronold, et al.
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 38
History repeating: A roadmap to address common problems in psychedelic science
Michiel van Elk, Eiko I. Fried
(2023)
Open Access | Times Cited: 23
Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING)
Mauro Pettorruso, Roberto Guidotti, Giacomo d’Andrea, et al.
Psychiatry Research (2023) Vol. 327, pp. 115378-115378
Open Access | Times Cited: 23
Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression
Alice Lineham, Victor J. Avila‐Quintero, Michael H. Bloch, et al.
Journal of Child and Adolescent Psychopharmacology (2024) Vol. 34, Iss. 2, pp. 73-79
Closed Access | Times Cited: 10
Hype or hope? High placebo response in major depression treatment with ketamine and esketamine: a systematic review and meta-analysis
Alexandros Matsingos, Marcel Wilhelm, Laila Noor, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 10
Repeated ( S )-ketamine administration ameliorates the spatial working memory impairment in mice with chronic pain: role of the gut microbiota–brain axis
Yubin Jiang, Xingming Wang, Jiawei Chen, et al.
Gut Microbes (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 9
Esketamine Nasal Spray in Major Depressive Disorder: A Meta‐Analysis of Randomized Controlled Trials
Zhibin Wang, Lili Jiang, Wei Ma, et al.
Clinical Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 1
Ketamine-assisted psychotherapy in adolescents with multiple psychiatric diagnoses
Philip E. Wolfson, Julane Andries, Daniel Ahlers, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 14
Clinical pharmacological innovation in the treatment of depression
Jeffrey M. Witkin, Lalit K. Golani, Jodi L. Smith
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 4, pp. 349-362
Closed Access | Times Cited: 13
Demographic and clinical predictors of response and remission in the treatment of major depressive disorder with ketamine and esketamine: A systematic review
Juliana Lima Constantino, Michael Godschalk, Jens H. van Dalfsen, et al.
Psychiatry Research (2025) Vol. 345, pp. 116355-116355
Open Access
Current evidence for the role of rapid-acting antidepressants (RAAD) in bipolar depression? A perspective and plan for action
Jonathan Repple, Maximilian Bayas, Christine Möser, et al.
Biological Psychiatry (2025)
Open Access
Repeated administration of esketamine ameliorates mechanical allodynia in mice with chemotherapy-induced peripheral neuropathy: A role of gut microbiota and metabolites
Wei-Wei Luan, Hanwen Gu, Di Qiu, et al.
Neurochemistry International (2025) Vol. 185, pp. 105961-105961
Closed Access
Let’s Move Towards Precision Suicidology
Philippe Courtet, Pilar A. Sáiz
Current Psychiatry Reports (2025)
Closed Access
Triple-network model–based graph theory analysis of the effectiveness of low-dose ketamine in patients with treatment-resistant depression: two resting-state functional MRI clinical trials
Shu–Chen Wei, Li‐Kai Cheng, Tung‐Ping Su, et al.
The British Journal of Psychiatry (2025), pp. 1-9
Closed Access
Brain-based correlates of antidepressant response to ketamine: a comprehensive systematic review of neuroimaging studies
Gustavo C. Medeiros, Malcolm Matheson, Isabella Demo, et al.
The Lancet Psychiatry (2023) Vol. 10, Iss. 10, pp. 790-800
Closed Access | Times Cited: 11
Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS
Adelaida Castillo, Julien Dubois, Ryan M. Field, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Functional changes in sleep-related arousal after ketamine administration in individuals with treatment-resistant depression
Elizabeth D. Ballard, Deanna Greenstein, Philip T. Reiss, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression
Manish K. Jha, Samuel T. Wilkinson, Kamini Krishnan, et al.
JAMA Network Open (2024) Vol. 7, Iss. 6, pp. e2417786-e2417786
Open Access | Times Cited: 3
Personalized use of ketamine and esketamine for treatment-resistant depression
Gustavo C. Medeiros, Isabella Demo, Fernando S. Goes, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Association of Neurofilament Light Chain With the Antidepressant Effects of Low-Dose Ketamine Infusion Among Patients With Treatment-Resistant Depression
Wei‐Chen Lin, Tung‐Ping Su, Cheng‐Ta Li, et al.
The International Journal of Neuropsychopharmacology (2023) Vol. 26, Iss. 9, pp. 649-653
Open Access | Times Cited: 8
Neurophysiological evidence that frontoparietal connectivity and GABA-A receptor changes underpin the antidepressant response to ketamine
Rachael L. Sumner, Rebecca McMillan, Anna Forsyth, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Predicting non-response to ketamine for depression: An exploratory symptom-level analysis of real-world data among military veterans
Eric A. Miller, Houtan Totonchi Afshar, Jyoti Mishra, et al.
Psychiatry Research (2024) Vol. 335, pp. 115858-115858
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top